Innovative Collaboration to Tackle Bird Flu Virus
In recent developments, Bioxytran, Inc. (OTCQB: BIXT), a pioneering biotechnology company, has signed an important Non-Disclosure Agreement (NDA) with the University of Georgia. This significant partnership focuses on evaluating Bioxytran's galectin antagonist as a potential treatment for chickens infected with the Bird Flu virus. This initiative is expected to leverage advanced research to combat avian influenza effectively.
Leading the Charge: Expertise from the University of Georgia
Dr. Daniel Perez will lead this collaborative research. He is well-recognized in the fields of virology and poultry medicine and holds esteemed positions at the University of Georgia, including his role as the CVI Affiliated Faculty and Caswell Eidson Chair in Poultry Medicine. His expertise is instrumental in guiding this innovative research project, which aims to explore the efficacy of Bioxytran's therapeutic solutions.
Understanding Galectin Antagonists
Bioxytran's flagship drug, ProLectin-M, functions as a novel galectin antagonist, specifically targeting galectins that play crucial roles in viral replication and inflammation. Early in vitro studies have shown promising results against viruses closely related to the Bird Flu virus. This evidence strengthens the case for its application in poultry and opens avenues for further exploration in treating viral infections more broadly.
Bioxytran's Vision in Biotherapeutics
Bioxytran is committed to addressing significant unmet medical needs, and its innovative approach centers around carbohydrate-based therapeutics. With a strong focus on glycovirology, cancer metastasis, and oxygen delivery, Bioxytran's research and development pipeline promises to enhance the landscape of treatment options available for various medical conditions. Beyond ProLectin-M, the company continually advances its programs targeting pulmonary fibrosis and stroke, showcasing its dedication to groundbreaking healthcare solutions.
Commitment to Research and Development
This NDA marks a pivotal moment for Bioxytran as it embarks on an important journey into the realm of avian health. Through dedicated research and strategic partnerships, the company intends to refine its therapeutic candidates and ultimately contribute positively to poultry health and, consequently, public health. Bioxytran’s collaborative efforts signify a step towards more sustainable solutions in agriculture and beyond.
Bioxytran’s Investor Relations
For those interested in learning more about Bioxytran and its future initiatives, the company’s investor relations are well-prepared to provide insights. Michael Sheikh, reachable at 509-991-0245 or via email, serves as the point of contact to address inquiries regarding the company’s progress and strategies. As Bioxytran continues to grow its network and expertise, keeping stakeholders informed remains a priority.
Frequently Asked Questions
What is the goal of Bioxytran’s partnership with the University of Georgia?
The partnership aims to evaluate Bioxytran’s galectin antagonists as a potential treatment for Bird Flu in chickens, enhancing avian health solutions.
Who leads the research at the University of Georgia?
Dr. Daniel Perez, a respected expert in virology and poultry medicine, leads the research effort in this collaboration.
What is ProLectin-M?
ProLectin-M is Bioxytran’s innovative drug candidate designed to inhibit galectins, which are involved in viral replication and inflammation, showing promise against bird flu viruses.
What other treatments is Bioxytran developing?
In addition to ProLectin-M, Bioxytran is advancing programs targeting pulmonary fibrosis and stroke, reflecting its commitment to addressing critical health issues.
How can investors get in touch with Bioxytran?
Investors can contact Michael Sheikh at 509-991-0245 or via email for insights and information regarding Bioxytran’s ongoing projects and plans.
